最后收盘
$1.22
2026-09-04 Nasdaq regular close；当日量 133,100 股。Yahoo 行情 API 本地快照。
CHAPTER 00
一页看懂
基本市值
$162.6m
133,242,324 股 × $1.22；股数以 2026-09-04 ATM 修正稿沿用的 2026-08-26 在外口径为准。
近似企业价值
$151.6m
基本市值减 2026-06-30 现金、可随时支取的 $4m CDs，再加当期负债；不是并购估值，也未更新 6/30 后现金变化。
期权性
战略交易已经写进正式披露
公司正评估对运营企业的投资或收购，也列出合作、业务收购及其他增长机会；这不是“已签交易”。
主要卖压
77.759m 已注册转售 + $100m ATM
两套无重叠转售注册合计占基本股本 58.36%；ATM 以 $1.14 例示可再发 87.719m 股。后者截至 9/4 明确为零售出。
现持仓
状态：在持；明细：未找到
本轮工单把 INDP 标为“在持票”，但全量本机会话、总线与 IBKR 结果未找到 Tony 的成交日期、数量、成本或浮盈亏。这里不倒推。
买入执行：未在本机找到，待 Tony 确认当前结论：INDP 的基本面锚已不是活跃临床管线，而是“现金壳 + 高度集中股权 + 战略交易选择权”。但这个选择权被 77.759m 可转售股份和 $100m ATM 夹住：上涨需要一个能吸收供给的具名资产/交易，单靠“正在评估”不足以改变结构。
三条最要紧的未定事项
截至 9/4 没有具名 Post-Investment Transaction。
9/4 还是 0；下一份 8-K / 10-Q 的股份与现金流是硬证据。
注册“可以卖”不等于“已经卖”；需要 13D/A、Form 4（如适用）及成交/股本变化验证。
CHAPTER 01
公司是什么
来历：Intec 变成 Decoy/Indaptus
2021-08-03，Delaware 注册的 Intec Parent 完成对 Decoy Biosystems 的反向收购：Merger Sub 并入 Decoy、Decoy 作为全资子公司存续，公司改名 Indaptus；Decoy 每股换 2.654353395 股上市公司普通股。交割后 5,405,963 股中，原 Decoy 股东约占 65.6%，原 Intec Israel 股东约 34.4%；8 月 4 日以 INDP 开始交易。2021 merger 8-K ↗
在这之前，Intec Pharma Ltd. 是以色列主体；domestication merger 后它成为 Delaware 母公司的全资子公司。当前注册人为 Delaware corporation，并以美国 domestic issuer 表格申报，而不是 FPI。2021 S-4 ↗ latest 8-K cover ↗
原业务与现在的真实状态
系统静脉给药、减毒灭活的非致病革兰阴性菌免疫刺激平台，目标是同时激活先天与适应性免疫。2022 年 FDA 放行 IND；2023 年首位受试者给药；2024 年进入重复给药并与 BeiGene/BeOne 的 tislelizumab 建立临床供药合作；2025 年组合研究首位患者给药。公司新闻稿 · 2022-05-19 ↗ 公司新闻稿 · 2024-10-22 ↗ 公司新闻稿 · 2025-06-02 ↗
现状 2026 Q2 已停止进一步入组，无任何活跃 Decoy20 临床研究参与者，也没有活跃临床开发项目；公司称短期研发费将下降。10-Q · no active program ↗
2026 Q2 与昆明理工大学开展神经与睡眠研究合作，定位为 Decoy 平台研究的延伸；未披露付款、里程碑、专利归属或商业化时间表。
项目清单：阶段、下一数据点
| 项目 | 适应症/主题 | 阶段 | 下一个可核数据点 | 时间 |
|---|---|---|---|---|
| Decoy20 单药 | 晚期实体瘤 | 已停止进一步临床开发 | 许可、合作、资产处置或重启决定 | 公司未给日期 |
| Decoy20 + tislelizumab | 既往 checkpoint 治疗 / 难响应实体瘤 | 停止入组；无人仍在活跃研究 | 终止/数据收尾、资产战略决定 | 公司未给日期 |
| 睡眠/神经合作 | 睡眠生物信号、神经生理、免疫状态 | 研究合作/评估 | 具体研究方案、数据、IP 或商业条款 | 公司未给日期 |
| Post-Investment Transaction | 运营企业投资/收购 | 搜寻与评估 | 具名 LOI / definitive agreement / closing | 公司未给日期 |
管理层与董事会（9/4 后）
台前负责人是 39 岁的 CEO/董事长 Junyi Dai：此前管理悉尼房地产投资/资管公司 FLMD，2024–2025 年任 Mega Matrix 独董。CFO 为 Yu Ding。9/2 Tim Ruan 辞任且公司称无分歧后，按最近代理材料减一人，董事会剩 Junyi Dai、Qinglai Lu、Jerome Jabbour、David Natan、Johnny Fox Arrowsmith 五人；这是根据两份连续文件的组合推断。DEF 14A · biographies ↗ 9/4 8-K · Ruan resignation ↗
CHAPTER 02
资本结构与股本史
授权普通股
1.000bn
2/26 股东会批准从 200m 提高；当前基本在外只占授权额度 13.3%。
基本在外
133.242m
截至 2026-08-26 的 ATM 文件口径。
非关联公众持股
38.594m
38,594,413 股，占 133,242,324 股的 28.97%；这是封面用于 Form S-3 General Instruction I.B.6 的 non-affiliate 口径，不等同于日常成交自由流通盘。
证券摊薄分母
135.120m
基本股 + 1.789m 在外权证 + 0.089m 在外期权；假定全部行权，不计行权现金。
证券 + 计划池敏感度
148.444m
证券摊薄分母再加 13.324m 的 2026 Plan 初始授权池；计划池是待授予容量，不是已发股，本页仅作上限敏感度。
Pre-funded / RSU
PF 0 · RSU 未列
Q2 文中称 June 2025 pre-funded 已全数行权；Q2 EPS 表的 221,005 是期内加权反稀释数，不是期末在外数。最新 prospectus 没有量化在外 RSU，故本页敏感度按 0；若后续披露非零 RSU，148.444m 会低估。
股本阶跃（均按 2025 年 1:28 拆股后可比口径）
2024-120.429mpost-split equivalent
2025-060.605mafter June financings
2025-091.642mpost-SEPA / ATM
2025-122.167mbefore preferred conversion
2026-03113.242m+111m preferred conversion
2026-06133.242m+20m private placement
2024-12 股数由后续 10-K 追溯重列；2026-03 一步增加 111m 来自 Lazar 优先股转换，不是现金二次注入；2026-06 再增 20m 为 $0.60 私募。2025 10-K ↗ 2026 Q2 10-Q ↗
当前经济持股（以 133,242,324 股重算）
| 持有人/类别 | 股数 | 重算占比 | 流通注册状态 |
|---|---|---|---|
| Yun Yao | 41,991,000 | 31.51% | not registered in the two 2026 resale statements |
| Sino Lion Ventures | 38,895,000 | 29.19% | all registered for resale Aug 26 |
| Junyi Dai · CEO/Chair | 11,250,000 | 8.44% | officer/director; not in those resale statements |
| Ting Yang | 11,250,000 | 8.44% | all registered for resale Jul 17 |
| Lina Deng | 5,550,000 | 4.17% | all registered for resale Jul 17 |
| David Lazar | 2,064,000 | 1.55% | all registered for resale Jul 17 |
| Seven June investors | 20,000,000 | 15.01% | all registered for resale Aug 26 |
| Legacy / other | 2,242,324 | 1.68% | residual |
Yun/Sino/Junyi/Ting/Lina 的原始股数来自 6/12 proxy 及后续 resale prospectus；June investors 来自 6/17 placement。表列是 SEC beneficial ownership / 经济持股口径；普通股每股一票。百分比由本页按最新 133,242,324 股重算，不表示这些人仍构成 13(d) group，也不把他们机械合并为共同表决权。proxy ownership & one-share-one-vote ↗ Aug resale prospectus ↗
权证、期权、股权计划
截至 6/30 的加权平均行权价 $19.57、加权剩余期限 4.0 年；没有一个统一到期日。已知融资批次分别到 2029-08-08、2029-11-25、2030-01-16 与 2030-07-27；其中 1,676,425 股权证在 2026-02-11 被降至完整 token $1.75，其余条款不变。在 $1.22 现价下仍价外约 43%。10-Q · remaining term ↗ 424B5 Amendment · exact warrant tokens ↗
加权行权价 $64.38、加权剩余期限 8.1 年，按当前价格深度价外。10-Q · option term ↗
8/10 已批准；初始预留预计 13,324,232 股（当时在外股的 10%），2027–2031 每年 1 月 1 日自动增加上年末股本的 5%，董事会可降至零。旧 2021 计划停止新授予。DEF 14A · plan ↗ 8-K · approval ↗
18.864m + 58.895m 都已包含在 133.242m 基本股本内，影响是可售供给；ATM 才会在真正售出时新增股本。
主要发行与融资
| 日期 | 工具 | 股/证券 | 价格 / 金额 | 投资人 / 去向 |
|---|---|---|---|---|
| 2021-08-03 | 私募 | 2.727m prefunded warrants + 2.727m warrants | $10.99 配对；$29.9m gross；该交易摘要未量化 net | 一名机构投资人；随 Decoy merger 关闭 |
| 2024-08-08 | 注册直发 + 私募权证 | 58,708 股 + 58,708 权证 | $51.10 配对；约 $3.0m gross / $2.5m 扣已披露费用后；权证 $47.60 | 若干投资人，含一名高管 |
| 2024-11-25 | 注册直发 + 私募权证 | 64,893 股 + 64,893 权证 | $32.90 配对；$2.13m gross / $1.785m 扣已披露费用后；权证 $29.40 | 若干投资人，含一名高管 |
| 2025-01-12 | 私募 | 75,335 股 + 75,335 权证 | $29.82 配对；$2.2465m gross / 约 $2.0m net；权证 $26.32 | 机构及 accredited investors |
| 2025-02 to 2026-03 | Yorkville SEPA | 89,902 股实际售出 | 约 $1.74m net；后终止 | YA II PN |
| 2025-06 | 可转债/权证私募 | 501,566 转股 + 190,795 prefunded + 1,384,722 warrants | 转换/行权锚 $8.3024；$5.7m gross / 约 $4.9m net（fees + expenses 约 $0.8m） | 若干投资人 |
| 2025-09 | 旧 ATM | 520,000 股 | 约 $2.3m gross / $2.25m net | 市场 |
| 2025-12-23 | AA/AAA 优先股 | 300k AA + 700k AAA → 111m 普通股 | $6.00/优先股；$6m gross；交易摘要未量化 net | David Lazar |
| 2026-03-23 | 二级控制权转售 | 896,800 优先股权益转让 | $11.2m，钱付给 Lazar、非公司 | Yun Yao 等五方 |
| 2026-06-17 | 普通股私募 | 20m 股 | $0.60；$12m gross / $11.984m net | 7 名非美 accredited investors |
| 2026-08-31 | 新 ATM | 额度 $100m；按 $1.14 例示 87.719m 股 | 市场价；3% commission | H.C. Wainwright；截至 9/4 售出 0 |
CHAPTER 03
申报时间线
EDGAR 分母
334
2021–2026 submissions 索引 accession 去重。
完整落盘
334 / 334
complete submission .txt；缺件 0；逐件头尾与 DOCUMENT 标签程序验证。
另一 CIK
327
Intec Pharma Ltd. CIK 0001638381 索引 327 件；依工单未扩目录。
表型 × 年份
| 年 | 10-K | 10-Q | 8-K | 8-K/A | S-3 | 424B3 | 424B5 | DEF 14A | PRE 14A | 3 | 4 | SCHEDULE 13D | SCHEDULE 13D/A | SCHEDULE 13G | SCHEDULE 13G/A | EFFECT | Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | – | 3 | 9 | 1 | 1 | 2 | – | – | – | 11 | 13 | – | – | – | – | 3 | 26 | 69 |
| 2022 | 1 | 3 | 11 | – | 2 | 1 | – | 1 | – | 2 | 18 | – | – | – | – | 3 | 13 | 55 |
| 2023 | 1 | 3 | 10 | – | – | – | 1 | 1 | – | 2 | 12 | – | – | – | – | – | 3 | 33 |
| 2024 | 1 | 3 | 12 | – | – | – | 4 | 1 | – | – | 18 | – | – | – | – | 2 | 13 | 54 |
| 2025 | 1 | 3 | 15 | – | 3 | – | 1 | 2 | 2 | 2 | 18 | – | 2 | 1 | – | 5 | 17 | 72 |
| 2026 | 1 | 2 | 14 | 1 | 2 | 1 | 2 | 2 | 2 | 7 | 5 | 2 | 6 | – | 1 | 2 | 1 | 51 |
SCHEDULE 13D/G 是新 XML 表型；SC 13D/G 是旧表型，因此分列。Other 含 S-1/S-4、CORRESP、UPLOAD、D、S-8、ARS 等。S-4 example ↗ Schedule 13D example ↗
承重关键件
| 日期 | 表型 | Accession | 一句话 |
|---|---|---|---|
| 2021-08-06 | 8-K | 0001493152-21-018937 ↗ | Decoy reverse acquisition closed; INDP became the listed name and $29.9m private placement closed. |
| 2025-06-26 | 8-K | 0001641172-25-016694 ↗ | 1-for-28 reverse split, post-split trading began June 27. |
| 2025-12-23 | 8-K | 0001493152-25-029107 ↗ | Lazar bought 1m preferred shares for $6m, convertible into 111m common shares; governance package attached. |
| 2026-02-27 | 8-K | 0001493152-26-008326 ↗ | Stockholders approved preferred conversion, 1bn authorized common shares, written consent and reverse-split authority. |
| 2026-03-24 | 8-K | 0001493152-26-012372 ↗ | Lazar resold most preferred rights for $11.2m; purchasers obtained 96.2%; management/board changed. |
| 2026-05-15 | 10-Q | 0001493152-26-023362 ↗ | $1.50m cash at March 31 after $7.01m Q1 operating cash use. |
| 2026-06-24 | 8-K | 0001493152-26-029918 ↗ | 20m shares sold at $0.60 for $12m gross; closing date June 17. |
| 2026-06-26 | S-3 | 0001493152-26-030346 ↗ | 18.864m-share resale registration for Ting Yang, Lina Deng and Lazar; effective July 17. |
| 2026-08-13 | 10-Q | 0001493152-26-037579 ↗ | Clinical enrollment stopped, no active Decoy20 program; strategic alternatives and sleep research collaboration disclosed. |
| 2026-08-17 | S-3 | 0001493152-26-038780 ↗ | 58.895m-share resale registration for seven June investors plus Sino Lion; effective August 25. |
| 2026-08-31 | 424B5 | 0001493152-26-040751 ↗ | $100m ATM prospectus; 3% sales commission. |
| 2026-09-01 | 8-K | 0001493152-26-040926 ↗ | $100m ATM agreement with H.C. Wainwright; no obligation to sell. |
| 2026-09-04 | 424B5 | 0001493152-26-041526 ↗ | Amendment corrected dilution math; expressly stated no ATM shares had yet been sold. |
| 2026-09-04 | 8-K | 0001493152-26-041532 ↗ | Tim Ruan resigned from the board effective September 2; no disagreement cited. |
CHAPTER 04
财务与现金
现金 + CDs
$11.55m
6/30 现金 $7.554m + 可随时支取 CDs $4.0m。
负债
$0.62m
6/30 total liabilities；较 12/31 的 $6.16m 大幅下降。
账面净值
$11.37m
约 $0.09/股；9/4 ATM 修正稿专门纠正了该稀释数学。
近八季（季度增量口径）
| 季度 | R&D | G&A | 经营现金流 | 期末现金 | 期末负债 | 来源 / 算法 |
|---|---|---|---|---|---|---|
| 2024 Q3 | $1.47m | $1.68m | $-2.51m | $7.38m | $2.24m | 0001493152-24-044537 ↗ reported quarter; OCF = 9M−6M |
| 2024 Q4 | $2.48m | $1.69m | $-3.40m | $5.79m | $3.39m | 0001493152-25-010136 ↗ derived FY−9M |
| 2025 Q1 | $2.81m | $1.76m | $-5.05m | $3.89m | $2.61m | 0001641172-25-010099 ↗ reported quarter |
| 2025 Q2 | $2.17m | $2.29m | $-4.02m | $6.16m | $8.51m | 0001641172-25-023333 ↗ R&D/G&A reported; OCF = 6M−Q1 |
| 2025 Q3 | $1.52m | $1.13m | $-2.57m | $5.83m | $2.23m | 0001493152-25-021759 ↗ R&D/G&A reported; OCF = 9M−6M |
| 2025 Q4 | $2.85m | $5.31m | $-3.19m | $8.51m | $6.16m | 0001493152-26-010585 ↗ derived FY−9M |
| 2026 Q1 | $0.49m | $1.67m | $-7.01m | $1.50m | $0.93m | 0001493152-26-023362 ↗ reported quarter |
| 2026 Q2 | $0.36m | $1.45m | $-1.93m | $7.55m | $0.62m | 0001493152-26-037579 ↗ R&D/G&A reported; OCF = 6M−Q1; excludes $4m CDs |
烧钱两口径：2026 上半年经营现金流出 $8.938m，即实际平均 $1.49m/月；但 Q2 单季增量只有 $1.928m，即 $0.64m/月，反映临床收缩和 Q1 清付应付款的基数差。用 $11.554m 流动资源机械相除分别约 7.8 个月与 18.0 个月；两者都不含未来收购/投资支出。公司自述则是可支持到 2027-06-30，并同时保留继续融资的可能。10-Q · cash flow and runway ↗
持续经营：尽管公司给出到 2027-06-30 的计划流动性口径，审阅报表仍明确说存在对持续经营能力的重大疑虑；两句话必须连读。10-Q · going concern ↗
CHAPTER 05
战略动作与交易
- Decoy reverse merger closes
The listed entity became Indaptus; Decoy holders owned 65.6%, old Intec holders 34.4%; a $29.9m placement closed.
- FDA clears Decoy20 IND
The company could begin the Phase 1 solid-tumor study.
- First subject dosed
Clinical execution began after the 2022 clearance.
- BeiGene supply agreement
Tislelizumab combination path added; Indaptus bore study costs other than supplied drug.
- First combination-study patient
Phase 1b/2 Decoy20 + tislelizumab dosing started.
- Partial response update
A monotherapy participant with urothelial cancer and liver metastases was highlighted.
- Lazar control financing
$6m preferred investment created 111m-share conversion capacity.
- Control sold onward
Most preferred rights transferred to five purchasers for $11.2m; 96.2% control followed.
- $12m placement
20m new shares sold at $0.60, taking basic shares to 133.242m.
- Clinical program becomes inactive
Enrollment stopped; no participant remained in an active study; Decoy20 development was substantially reduced.
- $100m ATM opened
The company gained a large discretionary market-issuance channel.
- ATM remains unused; director exits
No ATM shares sold as of the amendment; Tim Ruan’s resignation was separately filed.
交易主语与资金方向
2025-12 Lazar 投资给公司 $6m；2026-06 七名投资人再给公司 $12m gross。它们给了壳运营现金。
2026-03 五名购买人向 Lazar 支付 $11.2m 买优先股权益；这是二级交易，不进入公司现金。
$100m ATM 是上限，不是到账额；截至 9/4 售出 0。Post-Investment Transaction 也还没有具名对价或完成状态。
控制权从 Lazar 的过渡安排转到 Yun Yao、Sino Lion、Junyi Dai、Ting Yang、Lina Deng 五名购买人，交割后合计约 96.2%；Lazar 降到约 1.82%。之后 20m 私募把比例稀释，但没有改变 Yun + Sino 两者合计仍超过 60% 的经济持有（按现股数重算）。424B3 · transfer ↗
战略方向已经从“继续推进 Decoy20”变成多选：处置/许可旧资产、研究合作、投资或收购运营企业、数据型健康研究。昆明理工合作是唯一具名的新研究动作，但未披露商业对价；不能把它等同于资产注入。10-Q · alternatives ↗
CHAPTER 06
催化、风险与卖压方向
Bull path · 情景推演
具名交易吸收供给
出现可验证的运营资产、定价、融资、交割条件与 sponsor；交易叙事把需求从“猜壳”变成可估值标的。第一硬证据是 8-K 1.01/2.01、S-4 或具名收购 PR。
Base path · 情景推演
继续评估 + 低速烧钱
Decoy20 收缩让季度研发降至 $0.36m，现金按本页两种机械口径约支撑 7.8–18.0 个月；公司维持上市与研究合作，等待交易。10-Q · base inputs ↗
Bear path · 情景推演
转售 + ATM 先于资产
77.759m 老股逐步释放，同时公司启动 ATM；基本股本增加而新业务仍不具名，账面净值/股与控制集中度同步被摊薄。18.864m ↗ 58.895m ↗
ATM / Form S-3 I.B.6 公众流通市值口径
文件认定：8/31 的 424B5 与 9/4 修正稿均以 133,242,324 股总在外、其中非关联方持有 38,594,413 股，以及此前 60 日内 2026-07-02 收盘价 $3.03，计算公众流通市值约 $116,941,071.4。因该数高于 $75m，文件原文结论是截至各自日期“不受 General Instruction I.B.6 限制”。8/31 424B5 · I.B.6 ↗ 9/4 amendment · I.B.6 ↗
按本页现价机械重算：38,594,413 × $1.22 = $47,085,183.86（约 $47.09m），低于 $75m。I.B.6 条文后果仅是：如果该 $47.09m 成为适用的公众流通市值口径，则公司在任一连续 12 个月内依据 I.B.6 出售的证券价值不得超过该公众流通市值的三分之一，即机械值约 $15,695,061.29（约 $15.70m）；此前 12 个月内依据 I.B.6 已售证券计入该上限。本段不是新的 SEC/公司认定，也不推测公司是否会出售；原文件本身使用的是此前 60 日内的 $3.03。424B5 · one-third / 12 months ↗
谁需要高股价
| 角色 | 利益方向 | 可观测证据 |
|---|---|---|
| 公司 | 高价可减少 ATM 为同等现金发行的股数，也提高股票作为并购货币的效力。 | 424B5 售股数、10-Q financing cash flow、shares outstanding |
| 七名 $0.60 投资人 | $1.22 相对成本约 +103%；其 20m 股已注册可售，具备兑现动机。 | 8/26 resale prospectus、成交量与后续持股申报（如适用） |
| Sino Lion | 38.895m 股从 Lazar 权益链取得且全数注册；高价改善退出选择，但其持股规模本身足以压制流动性。 | 8/26 resale prospectus |
| Yun Yao / Junyi Dai | 未列入两套 resale；价值更依赖平台价格与后续资产。Junyi 同时控制经营决策。 | proxy 持股、未来 13D/A / Form 4 |
| 权证持有人 | 1.676m 股 $1.75 strike；股价需先超过行权价才有直接现金行权经济性。 | 10-Q/424B5 warrant disclosure |
可观测阈值
以下是本页为监控而设的分析阈值，不是公司指引；事实锚是当前 133.242m 股、ATM 例示价 $1.14 与 9/2 Nasdaq last sale $1.17。424B5 amendment · anchors ↗
- 正面：8-K 披露具名对手方、明确资产与 valuation；且融资价不低于交易前市场价。
- 中性转负：在没有具名资产前，基本股数比 133.242m 增加 >5% 或 financing cash inflow 显示 ATM 已启动。
- 供给警报：单日成交量持续超过 5m 股、同时价格无法守住 $1.14–$1.17（ATM 例示/修正稿价区）。
- 业务失效：下一季仍无具名交易，且现金+CDs 跌破 6 个月按 Q2 烧钱口径的覆盖。
- 治理警报：再有核心董事/高管辞任，或控制股东提交大幅减持的 13D/A。
CHAPTER 07
我们为什么买：决策史
边界：本章只还原当时怎么想，不拿旧分析证明今天的公司事实。首次关注、逻辑和守望线有原路径；真正成交日期/价/数量仍缺。
可证的逻辑链
首次关注出现在 2026-04-30 的 Lazar 案例横向研究：Tony 先问“indp呢”，随后形成“FIEE 和 INDP 像、买家可能不是最终交易方”的假设。/Users/tony/fleet-bus/web/dossiers/qucy-archive.html:283
5 月 17 日，关注点从结构故事推进到交易行为验证：要求从 3 月起跑 IBKR buy/sell、查 4 月起日线与“托盘迹象”，并问“有人看出来了想建仓？”。这说明当时的可证触发不是临床数据，而是控制权转手后的薄盘价格/成交异常。/Users/tony/fleet-bus/web/dossiers/qucy-archive.html:326-327
7 月 8 日的旧集成记录把正面路径写成“具名战略交易/资产注入/反向并购式转向”，负面路径写成“转售生效、折价增发或只有授权没有具名交易”。这是后续守望框架，不是本轮事实依据。/Users/tony/Dropbox/USstock/INDP/pk_codex_vs_claude_2026-07-08.md:64-78
8 月 26 日旧刷新记录到 58.895m 股转售登记，逻辑重心因此从“稀薄供给的壳选择权”转向“交易叙事必须先覆盖大规模可售供给”。/Users/tony/Dropbox/USstock/INDP/_refresh_2026-08-26_AirCodex01.md:22-30
不可证：没有找到 Tony 的 IB 成交、手记或总线持仓核对，无法还原买入执行、加减仓、均价和当前盈亏。当前“在持”只来自本轮任务状态；不得把控制人交易、历史讨论价或行情低点当成 Tony 成本。
decision_history.tsv 全表（11 行）
| 时刻 | 类型 | 原话/记录 | 源路径:行 | 价格/数量 |
|---|---|---|---|---|
| 2026-04-30 20:04:40 | 首次提及 | “indp呢” | /Users/tony/fleet-bus/web/dossiers/qucy-archive.html:283 | |
| 2026-04-30 20:04:40 | 买入理由前史 | “这么看fiee和indp确实比较像，买家可能不是最终的交易方。” | /Users/tony/fleet-bus/web/dossiers/qucy-archive.html:283 | |
| 2026-05-17 12:51:05 | 守望线 | “用本地ibkr跑一下indp这个股票3月1日开始的buy sell数据，分析是否有托盘迹象” | /Users/tony/fleet-bus/web/dossiers/qucy-archive.html:326 | |
| 2026-05-17 12:51:05 | 买入理由前史 | “在没有明显外部刺激的情况下，这种走势通常是什么原因；有人看出来了想建仓？” | /Users/tony/fleet-bus/web/dossiers/qucy-archive.html:326 | |
| 2026-05-17 13:34:49 | 买入理由前史 | “indp这组从lazar买东西的人以及机构，去sec查他们有没有别的交易记录，深度查” | /Users/tony/fleet-bus/web/dossiers/qucy-archive.html:327 | |
| 2026-06-14 12:40:09Z | 复盘 | “不要看其他agent的总结，完全从这些文件和必要的搜索信息，去梳理一下这个公司和股票的情况，让我对其能有充分的理解和认知。” | /Users/tony/Dropbox/USstock/INDP/historical_sessions/claude/recovered_2026-07-17/INDP stock analysis__1e86611a/audit.jsonl:115 | |
| 2026-07-08 | 逻辑变化 | “INDP is countable as a strategic-transition/shell-control-change ticker with substantial capital-markets optionality, but the setup is not cleanly bullish.” | /Users/tony/Dropbox/USstock/INDP/pk_codex_vs_claude_2026-07-08.md:64 | |
| 2026-07-08 | 守望线 | “Positive path: July 28 approval enables a named strategic transaction, asset injection, reverse-merger-style pivot, or credible external sponsor that creates enough narrative demand to overcome supply” | /Users/tony/Dropbox/USstock/INDP/pk_codex_vs_claude_2026-07-08.md:68 | |
| 2026-07-08 | 告警 | “Negative path: resale effectiveness, additional discounted issuance, or vague authorization without a named transaction dominates the tape.” | /Users/tony/Dropbox/USstock/INDP/pk_codex_vs_claude_2026-07-08.md:69 | |
| 2026-08-26 | 告警 | “登记售股股东转售最多 58,895,000 股，占登记时 133,242,324 股流通股约 44.2%。” | /Users/tony/Dropbox/USstock/INDP/_refresh_2026-08-26_AirCodex01.md:22 | 58,895,000 股 / 44.2% |
| 未在本机找到 | 买入执行 | “买入执行的日期、成交价和数量未在本机 IBKR 结果、会话与总线材料中找到，待 Tony 确认；不得据当前持仓状态反推。” | /Users/tony/Dropbox/USstock/INDP/codex/dossier_2026-09-05/history_scan_counts.tsv:1 | 未找到，待确认 |
CHAPTER 08
现持仓与守望线
数量 / 成本 / 浮盈亏
待确认
本机没有可靠成交件。若补到 IBKR statement，应以 account statement / execution 为唯一分母，不从“仓位预算”或对话价格推算。
现价
$1.22
2026-09-04 收盘；较 6/4 盘中高点 $5.96 低 79.5%，较 6/17 私募价 $0.60 高 103.3%。
下一定期件 · 本页估计
Q3 10-Q
季度截止 2026-09-30；公司尚未公告发布日。“11 月中旬”仅按往年申报节奏估计，不是公司指引，具体以 IR/SEC 为准。
价格与量能
日线：Yahoo Finance chart API，本地落盘。价格序列反映拆股调整；上层为收盘价、下层为成交量。关键事实价另以 SEC 424B5 的 Nasdaq last sale 交叉验证：9/2 为 $1.17。SEC price cross-check ↗
按文件守望
| 出现什么 | 立刻重看什么 | 含义 |
|---|---|---|
| 8-K 1.01 / 2.01 | 对手方、对价、股份数、closing conditions、终止权 | 验证是否终于从“评估”进入具名交易 |
| 424B5 / 10-Q 股本上升 | ATM gross/net、平均售价、期末股数 | 公司供给是否开始兑现 |
| 13D/A / Form 4 | Sino、Yun、Junyi、Ting、Lina、Lazar 的 disposition | 大股东是否出货或重新结盟 |
| 新 S-4 / merger proxy | pro forma ownership、估值、lock-up、PIPE | 后交易控制权和真正 fully diluted 分母 |
| Q3 10-Q | cash+CD、Q3 OCF、shares、ATM sales、战略费用 | 跑道与稀释两条线同时落地 |
CHAPTER 09
附录：全清单、方法、自检
100 篇公司新闻稿全清单 · 2021-08-03—2026-08-13
334 份 SEC complete-submission 全清单 · 2021-04-20—2026-09-04
| 日期 | 表型 | Accession | 主文档/说明 |
|---|---|---|---|
| 2026-09-04 | 8-K | 0001493152-26-041532 ↗ | 8-K |
| 2026-09-04 | 424B5 | 0001493152-26-041526 ↗ | 424B5 |
| 2026-09-01 | 8-K | 0001493152-26-040926 ↗ | 8-K |
| 2026-08-31 | 424B5 | 0001493152-26-040751 ↗ | 424B5 |
| 2026-08-26 | 424B3 | 0001493152-26-040246 ↗ | 424B3 |
| 2026-08-25 | EFFECT | 9999999995-26-002761 ↗ | xslEFFECTX01/primary_doc.xml |
| 2026-08-17 | S-3 | 0001493152-26-038780 ↗ | S-3 |
| 2026-08-13 | 10-Q | 0001493152-26-037579 ↗ | 10-Q |
| 2026-08-13 | 8-K | 0001493152-26-037574 ↗ | 8-K |
| 2026-07-17 | EFFECT | 9999999995-26-002348 ↗ | xslEFFECTX01/primary_doc.xml |
| 2026-07-16 | DEF 14A | 0001493152-26-033545 ↗ | DEF 14A |
| 2026-06-26 | SCHEDULE 13D/A | 0001829126-26-006953 ↗ | xslSCHEDULE_13D_X02/primary_doc.xml |
| 2026-06-26 | SCHEDULE 13D/A | 0001829126-26-006951 ↗ | xslSCHEDULE_13D_X02/primary_doc.xml |
| 2026-06-26 | SCHEDULE 13D/A | 0001829126-26-006950 ↗ | xslSCHEDULE_13D_X02/primary_doc.xml |
| 2026-06-26 | SCHEDULE 13D/A | 0001829126-26-006949 ↗ | xslSCHEDULE_13D_X02/primary_doc.xml |
| 2026-06-26 | S-3 | 0001493152-26-030346 ↗ | S-3 |
| 2026-06-24 | 8-K | 0001493152-26-029918 ↗ | 8-K |
| 2026-06-22 | PRE 14A | 0001493152-26-029633 ↗ | PRE 14A |
| 2026-06-05 | 8-K | 0001493152-26-027499 ↗ | 8-K |
| 2026-05-15 | 10-Q | 0001493152-26-023362 ↗ | 10-Q |
| 2026-05-15 | 8-K | 0001493152-26-023344 ↗ | 8-K |
| 2026-04-29 | SCHEDULE 13D/A | 0001829126-26-004104 ↗ | xslSCHEDULE_13D_X02/primary_doc.xml |
| 2026-04-24 | 8-K/A | 0001493152-26-018954 ↗ | 8-K/A |
| 2026-04-23 | 8-K | 0001493152-26-018608 ↗ | 8-K |
| 2026-04-20 | 3 | 0001829126-26-003665 ↗ | FORM 3 |
| 2026-04-06 | SCHEDULE 13G/A | 0001104659-26-039973 ↗ | xslSCHEDULE_13G_X02/primary_doc.xml |
| 2026-04-03 | 8-K | 0001493152-26-015079 ↗ | 8-K |
| 2026-04-02 | 3 | 0001493152-26-015004 ↗ | 3 |
| 2026-04-02 | 3 | 0001493152-26-015002 ↗ | 3 |
| 2026-04-02 | 3 | 0001493152-26-015000 ↗ | 3 |
| 2026-03-30 | SCHEDULE 13D | 0001829126-26-002858 ↗ | xslSCHEDULE_13D_X02/primary_doc.xml |
| 2026-03-24 | SCHEDULE 13D/A | 0001829126-26-002642 ↗ | xslSCHEDULE_13D_X02/primary_doc.xml |
| 2026-03-24 | 8-K | 0001493152-26-012372 ↗ | 8-K |
| 2026-03-24 | 4 | 0000921895-26-000788 ↗ | OWNERSHIP DOCUMENT |
| 2026-03-17 | 10-K | 0001493152-26-010585 ↗ | 10-K |
| 2026-03-02 | SCHEDULE 13D | 0001829126-26-001810 ↗ | xslSCHEDULE_13D_X01/primary_doc.xml |
| 2026-02-27 | 4 | 0001493152-26-008330 ↗ | 4 |
| 2026-02-27 | 8-K | 0001493152-26-008326 ↗ | 8-K |
| 2026-02-27 | 3 | 0001493152-26-008324 ↗ | 3 |
| 2026-02-26 | 3 | 0001829126-26-001660 ↗ | FORM 3 |
| 2026-02-13 | 4 | 0001493152-26-006707 ↗ | 4 |
| 2026-02-12 | DEFA14A | 0001493152-26-006332 ↗ | DEFA14A |
| 2026-02-12 | 8-K | 0001493152-26-006330 ↗ | 8-K |
| 2026-01-22 | 4 | 0001493152-26-003293 ↗ | 4 |
| 2026-01-22 | 4 | 0001493152-26-003292 ↗ | 4 |
| 2026-01-21 | DEF 14A | 0001493152-26-003135 ↗ | DEF 14A |
| 2026-01-20 | 8-K | 0001493152-26-002850 ↗ | 8-K |
| 2026-01-12 | 3 | 0001493152-26-001846 ↗ | 3 |
| 2026-01-08 | 8-K | 0001493152-26-001004 ↗ | 8-K |
| 2026-01-08 | PRE 14A | 0001493152-26-000999 ↗ | PRE 14A |
| 2026-01-02 | 8-K | 0001493152-26-000106 ↗ | 8-K |
| 2025-12-30 | SCHEDULE 13D/A | 0001493152-25-029594 ↗ | xslSCHEDULE_13D_X01/primary_doc.xml |
| 2025-12-30 | SCHEDULE 13D/A | 0001493152-25-029593 ↗ | xslSCHEDULE_13D_X01/primary_doc.xml |
| 2025-12-29 | 4 | 0001493152-25-029356 ↗ | 4 |
| 2025-12-29 | 4 | 0001493152-25-029355 ↗ | 4 |
| 2025-12-29 | 4 | 0001493152-25-029354 ↗ | 4 |
| 2025-12-29 | 4 | 0001493152-25-029353 ↗ | 4 |
| 2025-12-23 | 3 | 0001829126-25-010296 ↗ | FORM 3 |
| 2025-12-23 | 3 | 0001829126-25-010295 ↗ | FORM 3 |
| 2025-12-23 | 8-K | 0001493152-25-029107 ↗ | 8-K |
| 2025-11-12 | 10-Q | 0001493152-25-021759 ↗ | 10-Q |
| 2025-11-12 | 8-K | 0001493152-25-021758 ↗ | 8-K |
| 2025-09-04 | 8-K | 0001493152-25-012630 ↗ | 8-K |
| 2025-09-03 | S-1/A | 0001641172-25-026333 ↗ | S-1/A |
| 2025-09-02 | S-1 | 0001493152-25-012531 ↗ | S-1 |
| 2025-09-02 | 424B5 | 0001493152-25-012530 ↗ | 424B5 |
| 2025-08-20 | EFFECT | 9999999995-25-002695 ↗ | xslEFFECTX01/primary_doc.xml |
| 2025-08-20 | EFFECT | 9999999995-25-002694 ↗ | xslEFFECTX01/primary_doc.xml |
| 2025-08-19 | CORRESP | 0001641172-25-024756 ↗ | filename1.htm |
| 2025-08-19 | CORRESP | 0001641172-25-024754 ↗ | filename1.htm |
| 2025-08-18 | UPLOAD | 0000000000-25-008684 ↗ | filename1.pdf |
| 2025-08-18 | UPLOAD | 0000000000-25-008682 ↗ | filename1.pdf |
| 2025-08-13 | S-3 | 0001641172-25-023499 ↗ | S-3 |
| 2025-08-13 | S-3 | 0001641172-25-023490 ↗ | S-3 |
| 2025-08-13 | 10-Q | 0001641172-25-023333 ↗ | 10-Q |
| 2025-08-13 | 8-K | 0001641172-25-023332 ↗ | 8-K |
| 2025-07-29 | 8-K | 0001641172-25-021377 ↗ | 8-K |
| 2025-07-29 | 4 | 0001641172-25-021376 ↗ | xslF345X05/ownership.xml |
| 2025-07-16 | 8-K | 0001641172-25-019893 ↗ | 8-K |
| 2025-07-01 | 8-K | 0001641172-25-017283 ↗ | 8-K |
| 2025-06-26 | 8-K | 0001641172-25-016694 ↗ | 8-K |
| 2025-06-23 | DEF 14A | 0001641172-25-016071 ↗ | DEF 14A |
| 2025-06-20 | D | 0001641172-25-015841 ↗ | xslFormDX01/primary_doc.xml |
| 2025-06-13 | PRE 14A | 0001641172-25-014978 ↗ | PRE 14A |
| 2025-06-13 | 8-K | 0001641172-25-014972 ↗ | 8-K |
| 2025-06-11 | 4 | 0001641172-25-014695 ↗ | xslF345X05/ownership.xml |
| 2025-06-11 | 4 | 0001641172-25-014694 ↗ | xslF345X05/ownership.xml |
| 2025-06-11 | 4 | 0001641172-25-014693 ↗ | xslF345X05/ownership.xml |
| 2025-06-11 | 4 | 0001641172-25-014692 ↗ | xslF345X05/ownership.xml |
| 2025-06-11 | 4 | 0001641172-25-014691 ↗ | xslF345X05/ownership.xml |
| 2025-06-11 | 4 | 0001641172-25-014690 ↗ | xslF345X05/ownership.xml |
| 2025-06-11 | 8-K | 0001641172-25-014689 ↗ | 8-K |
| 2025-05-14 | 10-Q | 0001641172-25-010099 ↗ | 10-Q |
| 2025-05-14 | 8-K | 0001641172-25-010098 ↗ | 8-K |
| 2025-04-28 | ARS | 0001641172-25-006437 ↗ | formars.pdf |
| 2025-04-28 | DEFA14A | 0001641172-25-006433 ↗ | formdefa14a.htm |
| 2025-04-28 | DEF 14A | 0001641172-25-006429 ↗ | DEF 14A |
| 2025-04-17 | PRE 14A | 0001641172-25-005234 ↗ | formpre14a.htm |
| 2025-04-11 | 4 | 0001641172-25-003826 ↗ | xslF345X05/ownership.xml |
| 2025-04-11 | 4 | 0001641172-25-003825 ↗ | xslF345X05/ownership.xml |
| 2025-04-11 | 4 | 0001641172-25-003824 ↗ | xslF345X05/ownership.xml |
| 2025-04-11 | 4 | 0001641172-25-003823 ↗ | xslF345X05/ownership.xml |
| 2025-04-11 | 4 | 0001641172-25-003822 ↗ | xslF345X05/ownership.xml |
| 2025-04-11 | 4 | 0001641172-25-003821 ↗ | xslF345X05/ownership.xml |
| 2025-04-11 | 4 | 0001641172-25-003820 ↗ | xslF345X05/ownership.xml |
| 2025-03-27 | DRS | 0001641172-25-000975 ↗ | filename1.htm |
| 2025-03-13 | EFFECT | 9999999995-25-000662 ↗ | xslEFFECTX01/primary_doc.xml |
| 2025-03-13 | 8-K | 0001493152-25-010138 ↗ | form8-k.htm |
| 2025-03-13 | POS AM | 0001493152-25-010137 ↗ | formposam.htm |
| 2025-03-13 | 10-K | 0001493152-25-010136 ↗ | form10-k.htm |
| 2025-02-18 | SCHEDULE 13G | 0001104659-25-014739 ↗ | xslSCHEDULE_13G_X01/primary_doc.xml |
| 2025-02-13 | EFFECT | 9999999995-25-000450 ↗ | xslEFFECTX01/primary_doc.xml |
| 2025-02-13 | CORRESP | 0001493152-25-006307 ↗ | filename1.htm |
| 2025-02-12 | S-1 | 0001493152-25-006068 ↗ | forms-1.htm |
| 2025-02-12 | 8-K | 0001493152-25-006052 ↗ | form8-k.htm |
| 2025-02-12 | UPLOAD | 0000000000-25-001594 ↗ | filename1.pdf |
| 2025-02-11 | EFFECT | 9999999995-25-000402 ↗ | xslEFFECTX01/primary_doc.xml |
| 2025-02-11 | CORRESP | 0001493152-25-005834 ↗ | filename1.htm |
| 2025-02-07 | UPLOAD | 0000000000-25-001365 ↗ | filename1.pdf |
| 2025-02-05 | S-3 | 0001493152-25-005016 ↗ | forms-3.htm |
| 2025-01-31 | 8-K | 0001493152-25-004428 ↗ | form8-k.htm |
| 2025-01-22 | D | 0001493152-25-003248 ↗ | xslFormDX01/primary_doc.xml |
| 2025-01-14 | 8-K | 0001493152-25-002145 ↗ | form8-k.htm |
| 2024-12-31 | EFFECT | 9999999995-25-000021 ↗ | xslEFFECTX01/primary_doc.xml |
| 2024-12-30 | CORRESP | 0001493152-24-052452 ↗ | filename1.htm |
| 2024-12-30 | UPLOAD | 0000000000-24-014313 ↗ | filename1.pdf |
| 2024-12-23 | S-1 | 0001493152-24-051850 ↗ | forms-1.htm |
| 2024-12-06 | D | 0001857044-24-000003 ↗ | xslFormDX01/primary_doc.xml |
| 2024-11-26 | 4 | 0001493152-24-047808 ↗ | xslF345X05/ownership.xml |
| 2024-11-26 | SC 13D/A | 0001493152-24-047805 ↗ | formsc13da.htm |
| 2024-11-22 | 8-K | 0001493152-24-047422 ↗ | form8-k.htm |
| 2024-11-22 | 424B5 | 0001493152-24-047389 ↗ | form424b5.htm |
| 2024-11-12 | 10-Q | 0001493152-24-044537 ↗ | form10-q.htm |
| 2024-11-12 | 8-K | 0001493152-24-044533 ↗ | form8-k.htm |
| 2024-10-22 | 8-K | 0001493152-24-041886 ↗ | form8-k.htm |
| 2024-10-10 | SC 13D | 0001493152-24-040734 ↗ | formsc13d.htm |
| 2024-10-10 | 4 | 0001493152-24-040730 ↗ | xslF345X05/ownership.xml |
| 2024-10-10 | 4 | 0001493152-24-040729 ↗ | xslF345X05/ownership.xml |
| 2024-10-10 | 4 | 0001493152-24-040728 ↗ | xslF345X05/ownership.xml |
| 2024-10-10 | 4 | 0001493152-24-040727 ↗ | xslF345X05/ownership.xml |
| 2024-10-10 | 4 | 0001493152-24-040726 ↗ | xslF345X05/ownership.xml |
| 2024-10-04 | D/A | 0001857044-24-000002 ↗ | xslFormDX01/primary_doc.xml |
| 2024-09-20 | EFFECT | 9999999995-24-002917 ↗ | xslEFFECTX01/primary_doc.xml |
| 2024-09-18 | CORRESP | 0001493152-24-036982 ↗ | filename1.htm |
| 2024-09-17 | UPLOAD | 0000000000-24-010526 ↗ | filename1.pdf |
| 2024-09-12 | S-1 | 0001493152-24-036059 ↗ | forms-1.htm |
| 2024-08-22 | D | 0001857044-24-000001 ↗ | xslFormDX01/primary_doc.xml |
| 2024-08-12 | S-8 | 0001493152-24-031160 ↗ | forms-8.htm |
| 2024-08-12 | 10-Q | 0001493152-24-031158 ↗ | form10-q.htm |
| 2024-08-12 | 8-K | 0001493152-24-031157 ↗ | form-8k.htm |
| 2024-08-08 | 4 | 0001493152-24-030839 ↗ | xslF345X05/ownership.xml |
| 2024-08-08 | 8-K | 0001493152-24-030671 ↗ | form8-k.htm |
| 2024-08-07 | 424B5 | 0001493152-24-030613 ↗ | form424b5.htm |
| 2024-08-06 | 424B5 | 0001493152-24-030450 ↗ | form424b5.htm |
| 2024-06-07 | 4 | 0001493152-24-023152 ↗ | xslF345X05/ownership.xml |
| 2024-06-07 | 4 | 0001493152-24-023151 ↗ | xslF345X05/ownership.xml |
| 2024-06-07 | 4 | 0001493152-24-023150 ↗ | xslF345X05/ownership.xml |
| 2024-06-07 | 4 | 0001493152-24-023149 ↗ | xslF345X05/ownership.xml |
| 2024-06-07 | 4 | 0001493152-24-023148 ↗ | xslF345X05/ownership.xml |
| 2024-06-07 | 4 | 0001493152-24-023147 ↗ | xslF345X05/ownership.xml |
| 2024-06-07 | 8-K | 0001493152-24-023119 ↗ | form8-k.htm |
| 2024-05-22 | 8-K | 0001493152-24-020966 ↗ | form8-k.htm |
| 2024-05-08 | 10-Q | 0001493152-24-018162 ↗ | form10-q.htm |
| 2024-05-08 | 8-K | 0001493152-24-018161 ↗ | form8-k.htm |
| 2024-04-26 | DEFA14A | 0001493152-24-016073 ↗ | formdefa14a.htm |
| 2024-04-26 | DEF 14A | 0001493152-24-016072 ↗ | formdef14a.htm |
| 2024-03-25 | 8-K | 0001493152-24-011080 ↗ | form8-k.htm |
| 2024-03-13 | 424B5 | 0001493152-24-009844 ↗ | form424b5.htm |
| 2024-03-13 | 10-K | 0001493152-24-009769 ↗ | form10-k.htm |
| 2024-03-13 | 8-K | 0001493152-24-009766 ↗ | form8-k.htm |
| 2024-03-04 | 8-K | 0001493152-24-008670 ↗ | form8-k.htm |
| 2024-01-23 | 4 | 0001493152-24-003451 ↗ | xslF345X05/ownership.xml |
| 2024-01-23 | 4 | 0001493152-24-003450 ↗ | xslF345X05/ownership.xml |
| 2024-01-23 | 4 | 0001493152-24-003449 ↗ | xslF345X05/ownership.xml |
| 2024-01-23 | 4 | 0001493152-24-003447 ↗ | xslF345X05/ownership.xml |
| 2024-01-23 | 4 | 0001493152-24-003445 ↗ | xslF345X05/ownership.xml |
| 2024-01-23 | 8-K | 0001493152-24-003441 ↗ | form8-k.htm |
| 2023-11-06 | 10-Q | 0001493152-23-039523 ↗ | form10-q.htm |
| 2023-11-06 | 8-K | 0001493152-23-039517 ↗ | form8-k.htm |
| 2023-11-06 | 8-K | 0001493152-23-039445 ↗ | form8-k.htm |
| 2023-10-31 | 8-K | 0001493152-23-038800 ↗ | form8-k.htm |
| 2023-08-17 | SC 13G/A | 0001493152-23-029210 ↗ | formsc13ga.htm |
| 2023-08-16 | 4 | 0001493152-23-029212 ↗ | xslF345X05/ownership.xml |
| 2023-08-14 | 10-Q | 0001493152-23-028059 ↗ | form10-q.htm |
| 2023-08-14 | 8-K | 0001493152-23-028054 ↗ | form8-k.htm |
| 2023-08-10 | 8-K | 0001493152-23-027463 ↗ | form8-k.htm |
| 2023-08-07 | 4 | 0001493152-23-027061 ↗ | xslF345X05/ownership.xml |
| 2023-08-07 | 3 | 0001493152-23-027058 ↗ | xslF345X02/ownership.xml |
| 2023-05-30 | 4 | 0001493152-23-019463 ↗ | xslF345X04/ownership.xml |
| 2023-05-30 | 4 | 0001493152-23-019462 ↗ | xslF345X04/ownership.xml |
| 2023-05-30 | 4 | 0001493152-23-019461 ↗ | xslF345X04/ownership.xml |
| 2023-05-30 | 4 | 0001493152-23-019460 ↗ | xslF345X04/ownership.xml |
| 2023-05-30 | 4 | 0001493152-23-019459 ↗ | xslF345X04/ownership.xml |
| 2023-05-25 | 8-K | 0001493152-23-019073 ↗ | form8-k.htm |
| 2023-05-11 | 10-Q | 0001493152-23-016268 ↗ | form10-q.htm |
| 2023-05-11 | 8-K | 0001493152-23-016267 ↗ | form8-k.htm |
| 2023-04-12 | DEFA14A | 0001493152-23-011958 ↗ | formdefa14a.htm |
| 2023-04-12 | DEF 14A | 0001493152-23-011938 ↗ | formdef14a.htm |
| 2023-03-27 | 424B5 | 0001493152-23-009131 ↗ | form424b5.htm |
| 2023-03-24 | S-8 | 0001493152-23-008866 ↗ | forms-8.htm |
| 2023-03-23 | 8-K | 0001493152-23-008636 ↗ | form8-k.htm |
| 2023-03-17 | 10-K | 0001493152-23-008010 ↗ | form10-k.htm |
| 2023-03-17 | 8-K | 0001493152-23-008009 ↗ | form8-k.htm |
| 2023-02-14 | 4 | 0001493152-23-005058 ↗ | xslF345X03/ownership.xml |
| 2023-02-14 | 3 | 0001493152-23-005055 ↗ | xslF345X02/ownership.xml |
| 2023-02-14 | 8-K | 0001493152-23-004613 ↗ | form8-k.htm |
| 2023-01-20 | 4 | 0001493152-23-002023 ↗ | xslF345X03/ownership.xml |
| 2023-01-20 | 4 | 0001493152-23-002021 ↗ | xslF345X03/ownership.xml |
| 2023-01-20 | 4 | 0001493152-23-002020 ↗ | xslF345X03/ownership.xml |
| 2023-01-20 | 4 | 0001493152-23-002019 ↗ | xslF345X03/ownership.xml |
| 2022-12-30 | EFFECT | 9999999995-23-000016 ↗ | xslEFFECTX01/primary_doc.xml |
| 2022-12-30 | 424B3 | 0001493152-22-037167 ↗ | form424b3.htm |
| 2022-12-30 | CORRESP | 0001493152-22-036858 ↗ | filename1.htm |
| 2022-12-29 | UPLOAD | 0000000000-22-014001 ↗ | filename1.pdf |
| 2022-12-23 | S-1 | 0001493152-22-036488 ↗ | forms-1.htm |
| 2022-12-23 | 8-K | 0001493152-22-036486 ↗ | form8-k.htm |
| 2022-12-19 | 4 | 0001493152-22-035926 ↗ | xslF345X03/ownership.xml |
| 2022-11-22 | 4 | 0001493152-22-033241 ↗ | xslF345X03/ownership.xml |
| 2022-11-10 | 10-Q | 0001493152-22-031392 ↗ | form10-q.htm |
| 2022-11-10 | 8-K | 0001493152-22-031383 ↗ | form8-k.htm |
| 2022-10-03 | 4 | 0001493152-22-027441 ↗ | xslF345X03/ownership.xml |
| 2022-10-03 | 4 | 0001493152-22-027439 ↗ | xslF345X03/ownership.xml |
| 2022-10-03 | 4 | 0001493152-22-027438 ↗ | xslF345X03/ownership.xml |
| 2022-10-03 | 4 | 0001493152-22-027434 ↗ | xslF345X03/ownership.xml |
| 2022-10-03 | 4 | 0001493152-22-027432 ↗ | xslF345X03/ownership.xml |
| 2022-10-03 | 4 | 0001493152-22-027431 ↗ | xslF345X03/ownership.xml |
| 2022-09-30 | 8-K | 0001493152-22-027286 ↗ | form8-k.htm |
| 2022-09-12 | 4 | 0001493152-22-025578 ↗ | xslF345X03/ownership.xml |
| 2022-09-09 | EFFECT | 9999999995-22-002655 ↗ | xslEFFECTX01/primary_doc.xml |
| 2022-09-09 | RW | 0001493152-22-025489 ↗ | formrw.htm |
| 2022-09-09 | 4 | 0001493152-22-025450 ↗ | xslF345X03/ownership.xml |
| 2022-09-08 | 4 | 0001493152-22-025319 ↗ | xslF345X03/ownership.xml |
| 2022-09-07 | CORRESP | 0001493152-22-025240 ↗ | filename1.htm |
| 2022-09-07 | UPLOAD | 0000000000-22-009694 ↗ | filename1.pdf |
| 2022-09-01 | S-3 | 0001493152-22-024871 ↗ | forms-3.htm |
| 2022-08-08 | 10-Q | 0001493152-22-021562 ↗ | form10-q.htm |
| 2022-08-08 | 8-K | 0001493152-22-021561 ↗ | form8-k.htm |
| 2022-08-04 | DEFA14A | 0001493152-22-021369 ↗ | formdefa14a.htm |
| 2022-08-04 | DEF 14A | 0001493152-22-021368 ↗ | formdef14a.htm |
| 2022-07-21 | 8-K | 0001493152-22-020040 ↗ | form8-k.htm |
| 2022-07-08 | SC 13G/A | 0001903596-22-000443 ↗ | sc13g.htm |
| 2022-07-07 | 3 | 0001878961-22-000001 ↗ | PRIMARY DOCUMENT |
| 2022-06-07 | 4 | 0001493152-22-016027 ↗ | xslF345X03/ownership.xml |
| 2022-06-01 | 8-K | 0001493152-22-015627 ↗ | form8-k.htm |
| 2022-06-01 | S-3 | 0001493152-22-015610 ↗ | forms-3.htm |
| 2022-05-27 | AW | 0001493152-22-015353 ↗ | formaw.htm |
| 2022-05-19 | 8-K | 0001493152-22-014404 ↗ | form8-k.htm |
| 2022-05-12 | 10-Q | 0001493152-22-012931 ↗ | form10q.htm |
| 2022-05-12 | 8-K | 0001493152-22-012926 ↗ | form8-k.htm |
| 2022-03-25 | AW | 0001493152-22-007763 ↗ | formaw.htm |
| 2022-03-23 | EFFECT | 9999999995-22-000700 ↗ | xslEFFECTX01/primary_doc.xml |
| 2022-03-22 | POS AM | 0001493152-22-007456 ↗ | posam.htm |
| 2022-03-21 | POS AM | 0001493152-22-007380 ↗ | posam.htm |
| 2022-03-21 | 8-K | 0001493152-22-007323 ↗ | form8-k.htm |
| 2022-03-21 | 10-K | 0001493152-22-007319 ↗ | form10-k.htm |
| 2022-02-28 | 4 | 0001493152-22-005611 ↗ | xslF345X03/ownership.xml |
| 2022-02-11 | SC 13G/A | 0001213900-22-006682 ↗ | AMENDMENT NO. 2 TO SCHEDULE 13G |
| 2022-02-02 | 4 | 0001493152-22-003030 ↗ | xslF345X03/ownership.xml |
| 2022-02-02 | 3 | 0001493152-22-003028 ↗ | xslF345X02/ownership.xml |
| 2022-02-02 | 4 | 0001493152-22-003002 ↗ | xslF345X03/ownership.xml |
| 2022-02-01 | 8-K | 0001493152-22-002893 ↗ | form8-k.htm |
| 2022-01-28 | 4 | 0001493152-22-002556 ↗ | xslF345X03/ownership.xml |
| 2022-01-28 | 4 | 0001493152-22-002554 ↗ | xslF345X03/ownership.xml |
| 2022-01-28 | 4 | 0001493152-22-002550 ↗ | xslF345X03/ownership.xml |
| 2022-01-03 | 8-K | 0001493152-22-000039 ↗ | form8-k.htm |
| 2021-12-08 | 4 | 0001493152-21-030884 ↗ | xslF345X03/ownership.xml |
| 2021-12-08 | 3 | 0001493152-21-030883 ↗ | xslF345X02/ownership.xml |
| 2021-12-02 | 8-K | 0001493152-21-030260 ↗ | form8-k.htm |
| 2021-12-01 | EFFECT | 9999999995-21-004517 ↗ | xslEFFECTX01/primary_doc.xml |
| 2021-11-30 | POS AM | 0001493152-21-030102 ↗ | formposam.htm |
| 2021-11-19 | 4 | 0001493152-21-029297 ↗ | xslF345X03/ownership.xml |
| 2021-11-17 | SC 13D/A | 0001493152-21-029051 ↗ | formsc13da.htm |
| 2021-11-15 | 8-K | 0001493152-21-028326 ↗ | form8-k.htm |
| 2021-11-15 | 10-Q | 0001493152-21-028318 ↗ | form10-q.htm |
| 2021-10-26 | SC 13D/A | 0001493152-21-026354 ↗ | formsc13da.htm |
| 2021-10-26 | SC 13D/A | 0001493152-21-026353 ↗ | formsc13da.htm |
| 2021-10-26 | SC 13D/A | 0001493152-21-026352 ↗ | formsc13da.htm |
| 2021-09-30 | RW | 0001493152-21-024163 ↗ | formrw.htm |
| 2021-09-29 | EFFECT | 9999999995-21-003706 ↗ | xslEFFECTX01/primary_doc.xml |
| 2021-09-29 | 424B3 | 0001493152-21-024079 ↗ | form424b3.htm |
| 2021-09-28 | CORRESP | 0001493152-21-023937 ↗ | filename1.htm |
| 2021-09-27 | UPLOAD | 0000000000-21-011738 ↗ | filename1.pdf |
| 2021-09-24 | S-1 | 0001493152-21-023575 ↗ | forms-1.htm |
| 2021-09-16 | 4 | 0001493152-21-022936 ↗ | xslF345X03/ownership.xml |
| 2021-08-27 | S-8 | 0001493152-21-021456 ↗ | forms-8.htm |
| 2021-08-19 | SC 13D | 0001493152-21-020703 ↗ | formsc13d.htm |
| 2021-08-18 | POS AM | 0001493152-21-020550 ↗ | formposam.htm |
| 2021-08-16 | POS AM | 0001493152-21-020209 ↗ | formposam.htm |
| 2021-08-16 | S-3 | 0001493152-21-020181 ↗ | forms-3.htm |
| 2021-08-16 | 10-Q | 0001493152-21-020172 ↗ | form10-q.htm |
| 2021-08-16 | 8-K | 0001493152-21-020163 ↗ | form8-k.htm |
| 2021-08-16 | 8-K/A | 0001493152-21-020145 ↗ | form8-ka.htm |
| 2021-08-13 | SC 13D | 0001493152-21-019808 ↗ | formsc13d.htm |
| 2021-08-13 | SC 13D | 0001493152-21-019686 ↗ | formsc13d.htm |
| 2021-08-06 | 8-K | 0001493152-21-018937 ↗ | form8-k.htm |
| 2021-08-06 | 8-K | 0001493152-21-018935 ↗ | form8-k.htm |
| 2021-08-06 | 4 | 0001493152-21-018911 ↗ | xslF345X03/ownership.xml |
| 2021-08-06 | 4 | 0001493152-21-018910 ↗ | xslF345X03/ownership.xml |
| 2021-08-06 | 4 | 0001493152-21-018909 ↗ | xslF345X03/ownership.xml |
| 2021-08-06 | 4 | 0001493152-21-018908 ↗ | xslF345X03/ownership.xml |
| 2021-08-06 | 4 | 0001493152-21-018907 ↗ | xslF345X03/ownership.xml |
| 2021-08-06 | 4 | 0001493152-21-018906 ↗ | xslF345X03/ownership.xml |
| 2021-08-06 | 4 | 0001493152-21-018905 ↗ | xslF345X03/ownership.xml |
| 2021-08-06 | 4 | 0001493152-21-018904 ↗ | xslF345X03/ownership.xml |
| 2021-08-06 | 4 | 0001493152-21-018903 ↗ | xslF345X03/ownership.xml |
| 2021-08-06 | 4 | 0001493152-21-018902 ↗ | xslF345X03/ownership.xml |
| 2021-08-06 | 3 | 0001493152-21-018893 ↗ | xslF345X02/ownership.xml |
| 2021-08-06 | 3 | 0001493152-21-018892 ↗ | xslF345X02/ownership.xml |
| 2021-08-06 | 3 | 0001493152-21-018891 ↗ | xslF345X02/ownership.xml |
| 2021-08-05 | D | 0001493152-21-018744 ↗ | xslFormDX01/primary_doc.xml |
| 2021-08-03 | CERT | 0001354457-21-000892 ↗ | 8A_Cert_INDP.pdf |
| 2021-08-02 | 3 | 0001493152-21-018320 ↗ | xslF345X02/ownership.xml |
| 2021-08-02 | 3 | 0001493152-21-018319 ↗ | xslF345X02/ownership.xml |
| 2021-08-02 | 3 | 0001493152-21-018318 ↗ | xslF345X02/ownership.xml |
| 2021-08-02 | 3 | 0001493152-21-018317 ↗ | xslF345X02/ownership.xml |
| 2021-08-02 | 3 | 0001493152-21-018316 ↗ | xslF345X02/ownership.xml |
| 2021-08-02 | 3 | 0001493152-21-018315 ↗ | xslF345X02/ownership.xml |
| 2021-08-02 | 3 | 0001493152-21-018314 ↗ | xslF345X02/ownership.xml |
| 2021-07-29 | 425 | 0001493152-21-018115 ↗ | form8-k.htm |
| 2021-07-29 | 8-K | 0001493152-21-018114 ↗ | form8-k.htm |
| 2021-07-23 | 425 | 0001493152-21-017647 ↗ | form425.htm |
| 2021-07-23 | 8-K | 0001493152-21-017640 ↗ | form8-k.htm |
| 2021-07-23 | 8-A12B | 0001493152-21-017627 ↗ | form8a12b.htm |
| 2021-07-16 | 425 | 0001493152-21-017086 ↗ | form425.htm |
| 2021-07-16 | 8-K | 0001493152-21-017085 ↗ | form8-k.htm |
| 2021-06-28 | 10-Q | 0001493152-21-015394 ↗ | form10-q.htm |
| 2021-06-22 | 425 | 0001493152-21-014939 ↗ | form8-k.htm |
| 2021-06-22 | 8-K | 0001493152-21-014938 ↗ | form8-k.htm |
| 2021-05-14 | EFFECT | 9999999995-21-001955 ↗ | xslEFFECTX01/primary_doc.xml |
| 2021-05-14 | 424B3 | 0001493152-21-011556 ↗ | form424b3.htm |
| 2021-05-13 | CORRESP | 0001493152-21-011350 ↗ | filename1.htm |
| 2021-05-12 | S-4/A | 0001493152-21-011157 ↗ | forms-4.htm |
| 2021-04-22 | UPLOAD | 0000000000-21-005018 ↗ | filename1.pdf |
| 2021-04-20 | S-4 | 0001493152-21-009270 ↗ | forms-4.htm |
本机历史逐根全量扫描计数
| 根路径 | 扫描文件 | INDP 命中文件 |
|---|---|---|
~/.claude/projects/*/*.jsonl | 248 | 187 |
~/.codex/sessions/**/*.jsonl | 2672 | 880 |
~/Documents/cowork-recovered/** | 63330 | 448 |
~/Dropbox/USstock/INDP/historical_sessions/** | 43 | 20 |
~/Dropbox/USstock/INDP/claude/ (旧17件) | 17 | 9 |
~/Dropbox/USstock/INDP/codex/ (旧17件) | 17 | 10 |
INDP PK + refresh | 2 | 2 |
~/fleet-bus (排除双轨目标页) | NA | 61 |
计数由 scan_history.py 程序生成；current 对轨目录按盲规在遍历层剪枝。~/fleet-bus 行的 61 是 grep 命中文件数，未另报全仓总文件分母。
方法与分母
- SEC submissions 主索引 334 行、historical files 数组为空；按 accession 去重后 334，complete submission 落盘 334，缺 0。每件验证 SEC-DOCUMENT 头尾及 DOCUMENT 开闭配平。
- 另一 CIK：Intec Pharma Ltd. CIK 0001638381，官方 submissions 索引 327，依工单只记分母、不扩抓。
- PR：GlobeNewswire 公司组织页 99 篇 + SEC-only 2021-08-03 merger-close 公司新闻稿 1 篇 = 去重 100。IR/QuoteMedia 当前可见 60 篇作为交叉索引，不重复计数。
- 近八季 Q4 数是 FY−9M，Q2/Q3 OCF 是 YTD 差分；其余为报表直接季度值。所有差分算法明列在表。
- 历史扫描对指定根逐个文件完成；检索 current 对轨目录时在遍历层剪枝。本章只保存带路径和行号的候选。
程序化自检摘要
- PASS 章节 0–9 全存在；3 张图形：资本阶跃、事件时间线、价格量能。
- PASS SEC 334/334，PR unique 100；latest SEC = 2026-09-04。
- PASS 承重数字 6 处回查：133,242,324；$0.60 / 20,000,000 / $12,000,000；58,895,000；$100,000,000 / 87,719,298；$1.75 / 1,676,425；38,594,413 / $116,941,071.4 / $3.03。
- PASS 历史表每行 source:line 非空且引文 ≤200 字；缺成交字段明确写“未找到”。
- PASS 535 个外链均为 HTTPS、统一
target=_blank rel=noopener，并映射至本轮成功下载的 SEC/PR 原件或获准行情源；主题令牌、scroll-margin-top、移动端断点和 table 横向容器已设。 - external_http_requests: ≥730（来源：SEC 请求逐次日志 358；IR 浏览器 resource 235；GlobeNewswire 浏览器/fetch resource 133；Yahoo chart 1；另一 CIK submissions 1；两次顶层页面导航按纪律推断 2。浏览器 Performance 只保留 resource、未覆盖全部早期诊断与顶层导航，因此诚实报告可审计下限而非伪精确值。）
详细机器报文：~/Dropbox/USstock/INDP/codex/dossier_2026-09-05/selfcheck.txt。截图：screenshots/indp-codex-top.png、-middle.png、-bottom.png。
未解问题
- Tony 的成交日期、价、数量、账户与现浮盈亏。
- 截至 9/4 后 ATM 是否开始卖股、实际平均价与股数。
- 两套 resale registration 下实际售出多少；仅凭 registration 不能知道。
- Post-Investment Transaction 的对手方、资产、估值、资金来源、完成条件。
- 昆明理工合作的预算、IP、里程碑和商业化权利。
- Tim Ruan 辞任后的委员会构成和替代人选。
研究资料，不构成投资建议。数值 as-of 见页首；所有推断均以“推断/重算”标记，原始事实链接到 SEC 或公司新闻稿。